GovChime
Notice ID: a91b5a6c9e03445f8521e70cb6c5bcfbCombined Synopsis/Solicitation

DIABETES PROGRAM CONSULTANT

Archived on September 15, 2022. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
2:00 PM UTC−07:00
Posted
August 2, 2022
Notice type
Combined Synopsis/Solicitation
Set-aside
Small Business Set Aside - Total
NAICS
541990: All Other Professional, Scientific, and Technical Services
Agency
Department of Health and Human ServicesINDIAN HEALTH SERVICE

Notice details

Office
CALIFORNIA INDIAN HEALTH SERVICE
Place of performance
Sacramento, 95814
Last updated
Sep 25, 2026

Identifiers

Solicitation number
75H70322R00005
Notice ID
a91b5a6c9e03445f8521e70cb6c5bcfb

Description

All Proposal are to be submitted via email to Cordell.Bailey@ihs.gov This is a Total Small Business Set Aside with preference to Native American Owned Small Business per HHSAR 326.600-2 Buy Indian Act acquisition regulations. This clause is included in Full Text. All Small Businesses are encouraged to respond in the event no Native American Owned Small Business is successful. The Diabetes Program Consultant is a person with current knowledge and considerable experience that is acceptable by medical standards of practice. This Consultant is to be a reliable resource to the diabetes program staff and other medical providers working in California Tribal or urban healthcare centers. The Consultant must have knowledge of and experience working with federally funded Tribal and urban Indian healthcare clinics, and considerable knowledge of diabetes and prediabetes as it relates to American Indian/Alaska Native (AI/AN) populations is required. The Consultant must demonstrate knowledge and experience in diabetes education and care management, care coordination, and effective use of data. In addition, the Consultant must demonstrate proficiency in grant writing and grants management, and the ability to evaluate program capacity and effective and efficient use of program resources. The Consultant must demonstrate ability to teach these skills to others to support efforts in diabetes prevention and care, program management and resource utilization. To qualify for the position, a current health occupations license or registration (such as Registered Nurse, Physician Assistant, Physician, or Registered Dietitian) is required. Certification as a Diabetes Education and Care Specialist (CDECS), or an equivalent credential with expert knowledge and experience in diabetes care and education is required.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

No documents available.

Lifecycle

Solicitation:75H70322R00005
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 2, 2022

    DIABETES PROGRAM CONSULTANT

    Notice a91b5a6c9e03445f8521e70cb6c5bcfb on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Scope of Operations & Capabilities: Demonstrate capability to deliver all required services detailed in Section 5.0 (Requirements) of the PWS, including: Operating and maintaining a 24/7/365 toll-free intake hotline and online support (PWS 5.1.1). Providing timely referral services to qualified local providers within 60 miles of employee duty locations or homes of record throughout the State of Illinois (PWS 5.1.3 & 5.1.4). Providing up to five (5) counseling/coaching sessions per issue per employee, delivered by experienced and licensed counselors, with no extra billing (PWS 5.2.1 & 5.2.2). Timely quarterly usage and tracking reporting delivered to the COR within 30 calendar days of quarter end (PWS 5.3.1).
46%
Solicitation12/14/2026
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) seeks industry collaborators to provide novel therapeutic agents, diagnostic markers, biomarkers and devices for use in NIH-sponsored multi-center clinical trials and ancillary studies in patients with childhood cholestatic liver diseases, including biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis; and the liver disease related complications emanating from these diseases. BACKGROUND: The Childhood Liver Disease Research and Education Network (ChiLDReN) is a multi-center consortium of 10 clinical sites in the United States plus a scientific data coordinating center funded by NIDDK to study rare childhood liver diseases that result in cholestasis, including primary sclerosing cholangitis, biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, and idiopathic neonatal hepatitis. Five ongoing studies being conducted by ChiLDReN include: 1) A Prospective Database of Infants with Cholestasis (PROBE), a longitudinal observational study starting in infancy which has enrolled 890 infants with biliary atresia and 621 with intrahepatic cholestasis; 2) Biliary Atresia Study in Infants and Children (BASIC), a longitudinal study of children with biliary atresia both before and after liver transplant, which has enrolled over 1768 children with biliary atresia 3) Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC), a longitudinal study of intrahepatic cholestasis diseases, which has enrolled 474 subjects with Alagille syndrome, 572 with alpha-1 antitrypsin deficiency liver disease, 355 with PFIC and 36 with bile acid defects; 4) Longitudinal study of Mitochondrial Hepatopathies (MITOHEP) with 73 participants; and 5) Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH), a study of the prognostic value of hepatic ultrasound on the development of liver fibrosis in CF, which has enrolled over 770 subjects. In addition, ChiLDReN completed a placebo-controlled clinical trial to determine if post-operative corticosteroid therapy improves serum bilirubin and survival without liver transplantation in 140 infants with biliary atresia who have undergone the Kasai surgery ("START"). Ancillary studies to evaluate the natural history, clinical outcomes and quality of life, pathogenesis, genetics and genomics, proteomics, metabolomics, lipidomics, imaging studies, and determinants of progression and severity of these cholestatic liver diseases present a variety of research collaboration opportunities. ChilDReN is also interested in conducting clinical trials of promising therapies to improve clinical outcomes for these cholestatic liver diseases. Finally, improved diagnostics or screening procedures for biliary atresia and cholestasis in infants are of great interest to ChiLDReN. STUDY GOALS: The overall goal of ChiLDReN is to determine the etiology, genetics, pathogenesis, natural history, clinical outcomes, complications, predictors of outcomes and optimal therapy of the cholestatic liver diseases. ChiLDReN studies have enrolled and are following a relatively large and well characterized population of children and young adults with these rare disorders. ChiLDReN is interested in conducting research that will lead to improved clinical outcomes in children and young adults with these cholestatic liver diseases with industry collaborators to: • Evaluate the natural history, pathogenesis, diagnosis, genetic factors, genomics, proteomics, metabolomics, lipidomics, epigenomics, imaging studies, and determinants of progression and severity of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. • Explore use of serum markers for fibrosis and serum markers for disease activity to predict hepatic histology either by themselves or in combination with other clinical, laboratory, genomic, proteomic, metabolomic, and lipidomic variables • Explore the utility of these serum markers as surrogate markers of therapeutic response in study subjects participating in treatment trials (e.g., START study for biliary atresia) • Investigate proprietary drugs (such as novel choleretic agents, anti-fibrogenic agents, autophagy inducers, chloride channel inducers, fat-soluble vitamin supplements, bone mineral density agents, etc.), reagents, or devices in controlled randomized clinical trials as potential diagnostics or therapies for biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis • Evaluate novel newborn or infant screening techniques or devices for biliary atresia or cholestasis. • Evaluate noninvasive imaging methods for assessing fibrosis, biliary disease, and parenchymal pathology in these diseases including but not limited to the use of elastography, nuclear magnetic resonance imaging, and molecular imaging. • Evaluate the use of cytokine assays for analyses of serum/plasma cytokine levels as markers of disease activity and as surrogate markers of histologic or clinical improvement in therapeutic trials CAPABILITY STATEMENT: Commercial organizations interested in pursuing clinical collaborations with NIDDK for childhood cholestatic liver diseases are required to submit a Capability Statement to NIDDK. The Capability Statements submitted in response to this announcement will be used to evaluate and select industry collaborators. The Capability Statement should not exceed 10 (ten) pages of narrative (not including appendices) and should include the following information: 1. A description of the therapeutic, diagnostic or device proposed to be used in the clinical research study. (Note: The proposed therapeutic or device must have been tested already in a Phase I trial in humans.) 2. The specific details of the methods to be utilized in the investigation of the pharmacologic, surgical or device intervention in patients with biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis, and a clear description of all important issues surrounding the evaluation of disease progression in these patients. 3. A detailed plan demonstrating the ability to provide sufficient quantities of the therapeutic, diagnostic or device in a timely manner for the duration of the study. 4. A description of all laboratory tests that are needed, including assays and required amount of specimens, to determine specific biomarker levels along with appropriate methods for performing such tests. 5. A description of other core facilities and interactions with core facilities that are needed for the study. 6. Dosing and pharmacokinetic data from human studies for any novel therapeutics. 7. Adverse event profile for the proposed therapeutic or device. 8. A description of the practices and procedures that would be used to assure patient privacy and maintain confidentiality of data obtained from the study. 9. (Optional) Outcome measures of interest to the organization. The specifics of the proposed outcome measures should include but not be limited to treatment and evaluation of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. 10. Any other resources the organization proposes to commit to the collaboration (in addition to the proposed therapeutic, diagnostic or device), which may include any of the following: equipment, reagents, supplies, access to facilities, personnel or services, and, if appropriate, funding (pursuant to a Cooperative Research and Development Agreement (CRADA) authorized under 15 U.S.C. § 3710a), to help support the conduct of the clinical study. 11. Affirmative statements that the organization: a. agrees to provide a Letter of Cross Reference to the Drug, Biologic or Device Master File for the proposed therapeutic or device, which will be included with any US FDA filing by the IND or IDE Sponsor of the ChiLDReN study; b. agrees to have the proposed therapeutic, diagnostic or device used in ChiLDReN-developed protocols which will be conducted by the ChiLDReN research network for which the study data collection and analysis will be performed by the ChiLDReN Scientific and Data Coordinating Center; c. agrees to assure patient privacy and will maintain confidentiality of data obtained from the study; d. agrees to share all safety data from other studies involving the proposed therapeutic or device as well as relevant efficacy data from other studies (updated Investigator Brochure, etc) with the ChiLDReN; e. understands that because the ChiLDReN network is supported by NIDDK funding, the study results will be published and therefore agrees to the prompt publication of research results from the clinical study using the organization's proposed therapeutic, diagnostic or device; and f. understands that the clinical study will be conducted under an agreement with NIDDK which must adhere to PHS intellectual property policies (see: http://www.ott.nih.gov/policy/phspat_policy.aspx). SUBMISSION: Capability Statements received by NIDDK will be considered. Prospective collaborators may be invited to attend, at their own expense, a ChiLDReN Steering Committee meeting to be held in the Baltimore-Washington, DC area to discuss the information in their Capability Statement with the Steering Committee members. NOTE:NO FUNDS WILL BE PROVIDED BY NIDDK TO ANY ORGANIZATION SELECTED FOR THIS CLINICAL RESEARCH COLLABORATION OPPORTUNITY. SUBMISION AND INQUIRIES: Submit Capability Statements to: NOO Coordinator, National Institute of Diabetes and Digestive and Kidney Diseases e-mail: niddkottdip@niddk.nih.gov For Scientific Inquiries contact: Edward Doo, MD Director, Liver Diseases Research Program Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6149 Bethesda, MD 20892-5450 Telephone: (301) 451-4524 FAX: (301) 480-8300 e-mail: dooe@niddk.nih.gov Katrina Loh, MD Director, Pediatric Gastrointestinal and Liver Diseases Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6148 Bethesda, MD 20892-5450 Telephone: (301) 827-1079 FAX: (301) 480-8300 e-mail: katrina.loh@nih.gov For Inquiries Regarding Partnering with NIDDK (Intellectual Property Matters and Collaboration Agreements) contact: Agnes Rooke, JD Technology Advancement Office NIDDK, NIH, HHS Telephone: 301-451-6072 e-mail: Agnes.Rooke@nih.gov This Notice of Opportunity is also posted at: http://techdev.niddk.nih.gov/collabs.shtml.
42%
Special Notice05/31/2029
The Albuquerque Area Indian Health Services (AAIHS) will require professional healthcare (i.e., medically necessary outpatient/inpatient services) from local specialty health care providers & hospitals for the Purchase/Referred Care (PRC) eligible American Indian & Alaskan Natives. Services will not take place in IHS clinics or IHS hospitals, but at the Contractor's facility. The terms and conditions, as well as all other attachments required for this service are attached to this solicitation.
41%
Solicitation02/03/2027
This is not a solicitation announcement. This is a Sources Sought Notice (SSN) only. This SSN is issued solely for market research and planning purposes – it does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future. Further, the SSN does not commit the Government to contract for any supply or service whatsoever. The FDA is not seeking proposals and will not accept any unsolicited proposals. Responders are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this SSN; all costs associated with responding to this SSN will be solely at the expense of the interested respondents. Not responding to this SSN does not preclude participation in any future RFP, if issued. The purpose of this sources sought synopsis is to gain knowledge of potential qualified vendors to include potential 8(a) vendors 8(a) relative to the North American Industry Classification System (NAICS) code and capable of providing multidisciplinary scientific and regulatory professional services in support of FDA Centers and Offices. Responses to this Sources Sought Notice will be used by the Government to make appropriate determinations about potential sources. Project Title: FDA Scientific and Regulatory Support Services (SRS) IDIQ Background/Overview: The Food and Drug Administration (FDA) is a science-based regulatory agency critically important to the stability of the nation's public health and health care systems. FDA protects and promotes the health and safety of all Americans by enhancing the availability of safe medical products, foods, and animal products, and by promoting innovation that addresses unmet medical and public health needs. FDA decisions must be based on the best available scientific data and employ the best tools and methods available to ensure products meet the highest quality standards, while fostering innovation in the products it regulates. In support of its regulatory mission, FDA conducts scientific research across a broad range of disciplines including vaccines, drug safety, food safety, medical devices, biologics, toxicology, radiological products, and more. FDA's science is increasingly data-centric, complex, and collaborative, involving multidisciplinary groups across its Centers and Offices. Within the Center for Drug Evaluation and Research (CDER), the Office of Computational Science (OCS), established under the Office of Translational Sciences, supports the data management, technical, and analytic needs of the regulatory review process. OCS manages and supports analytical tools, data standards, and computing infrastructure that form the backbone of modern regulatory review for medical products. Purpose: The FDA is seeking information from experienced sources in Scientific and Regulatory Support Services as it is contemplating the establishment of a Indefinite Delivery Indefinite Quantity (IDIQ) to such services. The FDA’s primary objective for this effect is to obtain Contractor services related to scientific and regulatory support across a broad range of mission requirements. Depending on the requirement, services may support scientific research, regulatory review, clinical and non-clinical analyses, epidemiology and surveillance, scientific data interpretation, laboratory activities, technical writing, training, and scientific program coordination. Objectives: The objective of the contemplated SRS acquisition is to provide FDA with responsive, high-quality scientific and regulatory support across a broad range of mission requirements. Depending on the task order, services may support scientific research, regulatory review, clinical and nonclinical analyses, epidemiology and surveillance, scientific data interpretation, laboratory activities, technical writing, training, and scientific program coordination. The Government is interested in sources capable of providing the scientific depth and operational capacity needed to: Conduct scientifically sound analyses and prepare defensible, traceable technical products supporting FDA review and public-health decisions. Provide qualified personnel across multiple scientific and regulatory disciplines, including specialized and emerging areas. Support clinical and nonclinical study-data review, standardized scientific datasets, statistical computing, data fitness, quality assessment, and interpretation. Respond to multiple simultaneous task orders, changing priorities, time-sensitive scientific questions, and evolving requirements across FDA organizations. Maintain scientific quality, data integrity, documentation, confidentiality, and continuity of performance. Deliver effective scientific training, technical writing, knowledge transfer, and program-management support tied directly to scientific and regulatory missions. Project Requirements: The following descriptions are illustrative of the types of services that may be ordered. They are provided to inform industry responses and do not establish final task-order requirements. Each task order would define its own objectives, tasks, deliverables, performance expectations, staffing qualifications, and period of performance. Scientific Research and Regulatory Review Support: Support scientific investigations, literature and evidence reviews, research planning, study design, methodological assessments, scientific consultations, and technical analyses relevant to FDA-regulated products. Prepare scientific assessments, briefing materials, review support documentation, and other products that allow Government scientists and reviewers to evaluate scientific evidence and communicate findings. Provide subject-matter expertise to address complex or emerging regulatory science questions. Clinical and Nonclinical Study-Data Review and Analysis: Support the scientific review of clinical and nonclinical datasets submitted for regulatory purposes, including data fitness and completeness assessments, exploratory safety analyses, descriptive and inferential statistical analyses, and preparation of tables, listings, figures, and visualizations. Subject-matter expertise in applicable clinical and nonclinical study-data standards, including CDISC SDTM, ADaM, and SEND, is particularly relevant to these services. The RRS BPA describes review-oriented services that assess study data and produce analyses for FDA reviewers; SRS would focus on the scientific and analytical performance of those services rather than maintenance of the underlying software platforms. Epidemiology, Biostatistics, Pharmacovigilance, and Surveillance: Conduct epidemiological and Pharmacoepidemiological research, biostatistical analyses, pharmacovigilance assessments, signal detection and evaluation, public-health surveillance, and interpretation of real-world data and evidence as required by individual scientific programs. Activities may include protocol and analysis-plan support, assessment of study limitations and bias, statistical programming, results interpretation, and technical reporting. Scientific Data Standards, Quality, and Analytics: Provide scientific expertise related to data standards, controlled terminology, study-data interpretation, data quality and fitness, and reproducible analytical methods. Support scientific data preparation and validation, biostatistics, bioinformatics, computational science, and other specialized analyses when the primary deliverable is scientific or regulatory in nature. Distinguish these activities from enterprise database administration, application development, platform engineering, and IT operations. Laboratory and Specialized Scientific Support: Provide laboratory-related scientific and technical expertise, research assistance, analytical method support, study coordination, quality documentation, and interpretation or reporting of laboratory findings where required by a task order. Respondents should identify the specific laboratory disciplines, facilities, qualifications, and methods they can support rather than assume that all clinical trial operations or laboratory testing will be included. Scientific Writing, Training, Knowledge Management, and Communications: Develop scientific reports, regulatory review support materials, technical summaries, study documentation, research publications, presentations, training curricula, and knowledge-transfer materials. Provide specialized scientific and regulatory training, including instruction related to study-data standards and analytical methods. Communications and knowledge-management work should be directly connected to scientific or regulatory activities rather than general enterprise communications or IT support. Scientific Program and Project Management: Plan and coordinate scientific studies and projects; manage milestones, deliverables, schedules, staffing, and technical reporting; facilitate multidisciplinary collaboration; track performance and quality; and support continuity during transitions. Such activities must be integral to scientific and regulatory service delivery, not standalone enterprise IT project management. Scope Distinctions: The contemplated SRS acquisition is not intended to replace vehicles for enterprise IT architecture, systems or application development, cloud or data-platform operations, infrastructure administration, software maintenance, generalized service-desk support, or other predominantly IT functions. Where a task combines scientific analysis and enabling technology, the Government will determine the appropriate vehicle and scope based on the primary purpose of the requirement. The final boundary between SRS and remaining RRS or other vehicles is subject to FDA and OAGS confirmation. Capabilities and Technical Experience: Interested small businesses should submit a concise capability statement demonstrating relevant, actual performance and capacity to satisfy the contemplated requirements. Responses should clearly distinguish capabilities performed by the respondent from those provided by subcontractors, affiliates, or proposed teaming partners. FDA is particularly interested in the following: Relevant Experience: Describe comparable scientific and regulatory engagements, customer organizations, contract or order identifiers where releasable, approximate value, period of performance, work performed, disciplines supported, and measurable outcomes. Explain how the experience relates to the breadth and complexity of the contemplated SRS work. Scientific and Regulatory Disciplines: Describe the service areas the respondent can perform, with concrete examples involving scientific research, regulatory analysis, clinical and nonclinical datasets, statistical methods, epidemiology, laboratory work, scientific writing, and training as applicable. Do not claim disciplines for which experience cannot be substantiated. Workforce and Concurrent Delivery Capacity: Describe the organization's demonstrated ability to recruit, retain, and deploy highly specialized scientific and regulatory professionals across a broad range of disciplines, including individuals with advanced degrees, niche technical expertise, and experience supporting complex scientific and regulatory programs. FDA recognizes that certain highly specialized skill sets may require recruitment from an international talent pool, including individuals holding or requiring employment-based visa sponsorship (e.g., H-1B) or other appropriate work authorization. Respondents should describe their experience recruiting and retaining such personnel, managing applicable sponsorship and work authorization requirements, and mitigating potential staffing disruptions during contract transitions. Responses should also address the organization's ability to fill hard-to-recruit positions, maintain continuity of specialized expertise, accommodate surge requirements, and support multiple concurrent task orders. Where available, provide representative workforce metrics, such as available staffing capacity, average time-to-fill for specialized positions, and retention or attrition trends. Include a representative example demonstrating the organization's ability to respond to surge requirements or manage concurrent scientific and regulatory assignments, including its approach to staffing continuity, resource allocation, and timely delivery. Scientific Quality and Data Practices: Describe scientific quality-control procedures, independent review, data integrity and reproducibility practices, use of applicable scientific standards, confidentiality controls, and experience handling sensitive regulatory or research information. Representative Complex Requirement: Describe one or more specific scientific or regulatory assignments presenting substantial technical complexity, urgent timelines, multidisciplinary coordination, or simultaneous delivery requirements. Explain the challenge, approach, expertise, staffing considerations, deliverables, and outcomes. AI, Emerging Technology, and Responsible Use: Describe the organization's experience applying artificial intelligence (AI), machine learning (ML), or other emerging technologies to scientific research, regulatory review, or related analytical activities, as applicable. Provide representative examples of these applications and describe the organization's approaches to validating outputs, maintaining scientific integrity, ensuring appropriate human oversight, and managing associated risks. Identify any experience implementing responsible AI practices or governance frameworks, particularly in federal or regulated environments. Teaming and Prime-Contractor Role: Describe anticipated prime, subcontracting, joint-venture, or teaming arrangements and the work each participant would perform. Explain how the prime would exercise management and technical oversight while meeting applicable small-business requirements. Contract Structure Feedback: Identify whether the firm could support the full breadth of contemplated services or a defined subset and explain why. Instructions for Responses: Your responses to the questions provided below will assist the Government in selecting the appropriate acquisition method. Page limit: Maximum 15 pages (font size Times New Roman 11 or larger). A copy of the company capability statement will also be accepted (but not in place of the responses to the below questions). The anticipated period of performance is a 5-year ordering period. After review of the responses received, a pre-solicitation synopsis and formal solicitation may be published on SAM.gov. In addition to responses to the below questions, each vendor responding to this SSN shall also fill out and provide responses to “Attachment B-Vendor Feedback Form.” The Vendor Feedback Form is not included in the 15-page limit. A copy of the company capability statement will also be accepted (but not in place of the responses to the below questions or the Vendor Feedback Form). Responses to this notice must include company name, address, point of contact, size of business pursuant to the NAICS code, and must respond to the following questions: Is your business a small business under the NAICS code? Is your firm certified under Section 8(a) of the Small Business Act? Included is a draft Statement of Work that is inclusive of the anticipated Task Areas (Attachment A). All interested parties can provide written opinions on the draft Statement of Work. All opinions expressed should focus on strengthening the draft Statement of Work Tasks to ensure industry understands and comprehends the government’s requirements. Business Status Provide the legal business name and address Primary point of contact and the contact information SAM.gov Unique Entity Identifier (UEI) CAGE code Proposed NAICS code and size status Applicable small-business socioeconomic designations (including 8(a), HUBZone, service-disabled veteran-owned, veteran-owned, women-owned, or small disadvantaged business, as applicable) Identify whether the respondent proposes to participate as prime contractor, joint venture, or subcontractor Responses to this notice shall be submitted via e-mail to Amanda Edger, Contract Specialist, at Amanda.Edger@fda.hhs.gov (with a CC: to Ian Weiss, Contracting Officer, at Ian.Weiss@fda.hhs.gov), by November 23, 2026, at 2:00 pm EST. After a review of the received responses, a pre-solicitation synopsis and formal solicitation may be published on SAM.gov. No solicitation is currently available. This is not a request for proposals and in no way obligates the Government to award any contract. Responses to this Sources Sought Notice will not be considered adequate responses to the solicitation, a request to be added to a prospective offerors list, or a request to receive a copy of the solicitation. Ref. No. FDA-RFI-75F40127R00007/ALP No. OMITS-2027-136942.
38%
Market Research11/23/2026
38%
AwardedOpen

Additional Details

Solicitation Number

75H70322R00005

Archive Date

Sep 15, 2022

Office Address

SACRAMENTO, CA, 95814